Key statistics dashboard for AbbVie Inc. (ABBV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active...
Stock Data
| Price | $262.58 |
| Market Cap | $463.9B |
| Enterprise Value | $528.18B |
| Beta | 0.36 |
| Exchange | NYSE |
| Country | US |
Valuation Multiples
| P/E Ratio | 73.77 |
| Price / Book | -78.14 |
| P/S | 7.19 |
| EV/EBITDA | 24.87 |
| EV/Sales | 8.20 |
| EV/FCF | 26.84 |
| P/FCF | 23.51 |
| Earnings Yield | 1.36% |
| FCF Yield | 4.24% |
| Dividend Yield | 2.61% |
Profitability
| Gross Margin | 71.48% |
| EBIT Margin | 20.68% |
| EBITDA Margin | 32.98% |
| Operating Margin | 29.32% |
| Net Margin | 9.81% |
| Return on Equity | -136.50% |
| Return on Assets | 4.67% |
| Return on Invested Capital | 13.46% |
| Return on Capital Employed | 20.19% |
Financial Health
| Current Ratio | 0.81 |
| Quick Ratio | 0.69 |
| Cash Ratio | 0.16 |
| Debt / Equity | -11.93 |
| Debt / Assets | 52.41% |
| Net Debt / EBITDA | 3.03 |
| Interest Coverage | 6.47 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.43 |
Per-Share Data
| Revenue per share | 36.36 |
| Book Value per share | -3.31 |
| Cash per share | 3.71 |
| FCF per share | 11.11 |
| Tangible Book Value per share | -51.12 |
| Dividend per share | 6.83 |
Related companies: AMGN · AZN · GILD · JNJ · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of ABBV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks